Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (AGN). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Allergan Inc Exploring Sale Of Obesity Business-Reuters
Reuters reported that Allergan Inc was exploring a sale of its obesity business on falling sales of the only product in the unit. The Company expects sales of $160 million from its obesity intervention products unit for the full year. It sees total product net sales of between $5.69 billion and $5.77 billion.
Latest Developments for Allergan Inc
- Allergan Inc Raises Low End Of Prior FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Lowers FY 2013 EPS Guidance; Issues Q2 2013 Guidance; EPS Guidance Below Analysts' Estimates
- Allergan Inc Issues Q1 2013 Mixed Guidance; Issues FY 2013 Guidance Below Analysts' Estimates
- Allergan Inc Commences Cash Tender Offer For All Outstanding Shares Of MAP Pharmaceuticals
- Allergan Inc To Acquire MAP Pharmaceuticals Inc
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters